Big pharma, Partnering, Pharma

Otsuka and ARIAD signs pharma deals for Iclusig

Posted on 23 December 2014

Tags: , , ,

ARIAD Pharmaceuticals signs pharma deals with big pharma Otsuka to commercialize ARIAD’s Iclusig (ponatinib) in Japan and nine other Asian countries and to fund future clinical trials in those countries.

ARIAD will lead the completion of the Japanese New Drug Application for Iclusig, and Otsuka will file the NDA on behalf of both companies for regulatory approval in resistant and intolerant chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in 2015.

Iclusig is an approved BCR-ABL inhibitor in the United States, Europe and Australia.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

The pharma deals agreement provides for Otsuka to receive exclusive rights to market Iclusig in Japan and nine other Asian countries in return for an upfront payment of $77.5 million to ARIAD, a milestone payment upon regulatory approval in Japan for patients with resistant and intolerant Philadelphia-positive leukemias, and additional milestone payments for approval in other indications.

Following approvals in the Territory, Otsuka will conduct sales activities and record sales.

ARIAD will also receive a substantial share of net product sales.

ARIAD will continue to fund the completion of its ongoing pivotal trial of Iclusig that will form the basis of the filing for regulatory approval in Japan, while Otsuka will fund additional agreed-upon clinical studies in the Territory.

For ARIAD-sponsored global studies that include sites in Japan, Otsuka has the option to contribute to the funding and gain access to the data for use in the Territory.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Report:   Top 50 Big Pharma Partnering and M&A Deal Trends

Report:   Top 50 Big Biotech Partnering and M&A Deal Trends

Print Friendly, PDF & Email

Leave a Reply